We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.78 | 1.83% | 43.35 | 43.515 | 42.75 | 42.92 | 6,320,431 | 22:41:03 |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) Wednesday said it began a late-stage study to evaluate the effectiveness of Eltrombopag--a drug marketed as Promacta in the U.S. and Revolade in Europe--on people with myelodysplastic syndromes, or MDS, a type of cancer in which the bone marrow doesn't make enough healthy blood cells.
The "phase three" study will examine the drug's effectiveness in boosting platelet production in combination with azacitidine, an existing medicine, GSK said.
Shares at 0840 GMT down 13 pence or 0.8% at 1,564 pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
